<scp>ANA</scp> Investigates: Neurological Complications of <scp>COVID</scp>‐19 Vaccines

Goss, Adeline; Samudralwar, Rohini; Das, Rohit R.; Nath, Avindra

doi:10.1002/ana.26065

Cited by 165 publications

(136 citation statements)

References 6 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Though rare, mild and severe neurological side effects have been occasionally reported. 2 Search platforms and data bases to detect scientific reports about neurological adverse events may not be particularly helpful and do not provide many hits, but thorough assessments of various publications and their reference lists may help to find appropriate publications. Data from the mRNA vaccine clinical trials showed that 7 cases out of 37,000 vaccine recipients developed Bell's palsy.…”

mentioning

confidence: 99%

“…Data from the mRNA vaccine clinical trials showed that 7 cases out of 37,000 vaccine recipients developed Bell's palsy. 2 In the DNA-based Johnson & Johnson vaccine trial, one patient each in the vaccinated and placebo group developed Guillain-Barre syndrome (GBS). 2 According to the FDA Adverse Event Reporting System (FAERS), 9442 reports of adverse reactions to the vaccines have been submitted to VAERS as of March 2, 2021.…”

mentioning

confidence: 99%

“…2 In the DNA-based Johnson & Johnson vaccine trial, one patient each in the vaccinated and placebo group developed Guillain-Barre syndrome (GBS). 2 According to the FDA Adverse Event Reporting System (FAERS), 9442 reports of adverse reactions to the vaccines have been submitted to VAERS as of March 2, 2021. 2 The most common neurological symptoms included dizziness, headache, pain, muscle spasms, myalgia and paresthesias, which are expected to occur as acute, transient effects of the vaccination.…”

mentioning

confidence: 99%

“…2 According to the FDA Adverse Event Reporting System (FAERS), 9442 reports of adverse reactions to the vaccines have been submitted to VAERS as of March 2, 2021. 2 The most common neurological symptoms included dizziness, headache, pain, muscle spasms, myalgia and paresthesias, which are expected to occur as acute, transient effects of the vaccination. Rare cases of tremor, diplopia, tinnitus, dysphonia, seizures and reactivation of herpes zoster have been also reported.…”

mentioning

confidence: 99%

“…There were also cases of stroke (n = 17), GBS (n = 32), facial palsy (n = 190), transverse myelitis (n = 9) and acute disseminated encephalomyelitis (ADEM) (n = 6) in the VAERS database. 2 In a trial with the Sinovac and Sinopharm vaccines, 68% of participants reported post-vaccination headache and 60% had myalgia. 3 In the coronavirus vaccine trial, 2 patients with transverse myelitis were reported.…”

mentioning

confidence: 99%

See 4 more Smart Citations

SARS‐CoV‐2 vaccines are not free of neurological side effects

Finsterer

Scorza

2021

Acta Neurol Scand

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

SARS‐CoV‐2 vaccines are not free of neurological side effects

Finsterer

Scorza

2021

Acta Neurol Scand

View full text Add to dashboard Cite

show abstract

Association of New-Onset Seizures With SARS-CoV-2 Vaccines

Rafati,

Jameie,

Amanollahi

et al. 2024

JAMA Neurol

View full text Add to dashboard Cite

ImportanceSeizures have been reported as an adverse effect of the SARS-CoV-2 vaccine. However, no study has answered the question of whether there is any association between seizures in the general population and COVID-19 vaccination.ObjectiveTo evaluate the seizure incidence among SARS-CoV-2 vaccine recipients compared with those who received a placebo.Data SourcesA systematic search of MEDLINE (via PubMed), Web of Science, Scopus, Cochrane Library, Google Scholar, review publications, editorials, letters to editors, and conference papers, along with the references of the included studies from December 2019 to July 7, 2023.Study SelectionRandomized clinical trials (RCTs) reporting seizure incidence with SARS-CoV-2 vaccination were included.Data Extraction and SynthesisThis study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses framework and used the Mantel-Haenszel method with random- and common-effect models. The risk of bias of the studies was assessed using the Cochrane assessment tool for RCTs.Main Outcomes and MeasuresThe outcome of interest was new-onset seizure incidence proportion compared among (1) SARS-CoV-2 vaccine recipients and (2) placebo recipients.ResultsSix RCTs were included in the study. Results of the pooled analysis comparing the incidence of new-onset seizure between the 63 521 vaccine and 54 919 placebo recipients in the 28-day follow-up after vaccine/placebo injection showed no statistically significant difference between the 2 groups (9 events [0.014%] in vaccine and 1 event [0.002%] in placebo recipients; odds ratio [OR], 2.70; 95% CI, 0.76-9.57; P = .12; I2 = 0%, τ2 = 0, Cochran Q P = .74). Likewise, in the entire blinded-phase period after injection, with a median of more than 43 days, no significant difference was identified between the vaccine and placebo groups regarding incident new-onset seizure (13/43 724 events [0.03%] in vaccine and 5/40 612 [0.012%] in placebo recipients; OR, 2.31; 95% CI, 0.86-3.23, P &gt; .99, I2 = 0%, τ2 = 0, Cochran Q P = .95).Conclusions and RelevanceAccording to this systematic review and meta-analysis, there was no statistically significant difference in the risk of new-onset seizure incidence between vaccinated individuals and placebo recipients.

show abstract